Works by Heerspink, Hiddo J. L.
Results: 166
Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
- Published in:
- Nephrology, 2023, v. 28, n. 2, p. 97, doi. 10.1111/nep.14130
- By:
- Publication type:
- Article
When drug treatments bias genetic studies: Mediation and interaction.
- Published in:
- PLoS ONE, 2019, v. 14, n. 8, p. 1, doi. 10.1371/journal.pone.0221209
- By:
- Publication type:
- Article
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2019, v. 42, n. 10, p. 1921, doi. 10.2337/dc19-0937
- By:
- Publication type:
- Article
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography-Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01949-7
- By:
- Publication type:
- Article
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01916-2
- By:
- Publication type:
- Article
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01619-0
- By:
- Publication type:
- Article
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01481-0
- By:
- Publication type:
- Article
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e2310877, doi. 10.1001/jamanetworkopen.2023.10877
- By:
- Publication type:
- Article
[18F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus.
- Published in:
- Molecular Imaging & Biology, 2021, v. 23, n. 1, p. 117, doi. 10.1007/s11307-020-01538-0
- By:
- Publication type:
- Article
Indirect Insulin Resistance Indices and Their Cut-Off Values for the Prediction of Post-Transplantation Diabetes Mellitus in Kidney Transplant Recipients.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7296, doi. 10.3390/jcm12237296
- By:
- Publication type:
- Article
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives.
- Published in:
- Biomedicines, 2023, v. 11, n. 9, p. 2498, doi. 10.3390/biomedicines11092498
- By:
- Publication type:
- Article
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 5, p. 747, doi. 10.3390/jpm13050747
- By:
- Publication type:
- Article
Fasting Proinsulin Independently Predicts Incident Type 2 Diabetes in the General Population.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 7, p. 1131, doi. 10.3390/jpm12071131
- By:
- Publication type:
- Article
Kinetics of endothelin-1 and effect selective ET<sub>A</sub> antagonism on ET<sub>B</sub> activation: a mathematical modeling analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1332388
- By:
- Publication type:
- Article
Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.
- Published in:
- Cardiovascular Drugs & Therapy, 2020, v. 34, n. 3, p. 311, doi. 10.1007/s10557-020-06954-6
- By:
- Publication type:
- Article
The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 511, doi. 10.1111/dom.16041
- By:
- Publication type:
- Article
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3371, doi. 10.1111/dom.15678
- By:
- Publication type:
- Article
Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2741, doi. 10.1111/dom.15592
- By:
- Publication type:
- Article
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2128, doi. 10.1111/dom.15518
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. C1, doi. 10.1111/dom.15489
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 924, doi. 10.1111/dom.15387
- By:
- Publication type:
- Article
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 576, doi. 10.1111/dom.15346
- By:
- Publication type:
- Article
Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3779, doi. 10.1111/dom.15273
- By:
- Publication type:
- Article
The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3724, doi. 10.1111/dom.15267
- By:
- Publication type:
- Article
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3327, doi. 10.1111/dom.15232
- By:
- Publication type:
- Article
Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3152, doi. 10.1111/dom.15209
- By:
- Publication type:
- Article
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3064, doi. 10.1111/dom.15180
- By:
- Publication type:
- Article
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2419, doi. 10.1111/dom.15110
- By:
- Publication type:
- Article
Effects of albuminuria‐lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2413, doi. 10.1111/dom.15109
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2218, doi. 10.1111/dom.15099
- By:
- Publication type:
- Article
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2410, doi. 10.1111/dom.15103
- By:
- Publication type:
- Article
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091
- By:
- Publication type:
- Article
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1758, doi. 10.1111/dom.15033
- By:
- Publication type:
- Article
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post‐hoc study from the CANVAS programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1638, doi. 10.1111/dom.15018
- By:
- Publication type:
- Article
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1413, doi. 10.1111/dom.14978
- By:
- Publication type:
- Article
Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 198, doi. 10.1111/dom.14864
- By:
- Publication type:
- Article
Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1950, doi. 10.1111/dom.14779
- By:
- Publication type:
- Article
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1927, doi. 10.1111/dom.14772
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1429, doi. 10.1111/dom.14731
- By:
- Publication type:
- Article
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1578, doi. 10.1111/dom.14729
- By:
- Publication type:
- Article
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1360, doi. 10.1111/dom.14712
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1072, doi. 10.1111/dom.14671
- By:
- Publication type:
- Article
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 983, doi. 10.1111/dom.14660
- By:
- Publication type:
- Article
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 827, doi. 10.1111/dom.14641
- By:
- Publication type:
- Article
Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1961, doi. 10.1111/dom.14411
- By:
- Publication type:
- Article